Sionna Therapeutics, Inc. (SION)
Sionna Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Waltham, MA, US. The stock last traded at $6.05, up 18.63% on the session, giving a market capitalisation of $273.2M. On trailing twelve-month figures it carries a trailing P/E of -2.78, a net margin of 0.0%. Its beta of 1.32 implies it has historically moved more than the broad market.
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
Sionna Therapeutics, Inc. is most often compared with the following Healthcare names: